Sfoglia per AUTORE
LAUDANI ME
Collezione AO Ordine Mauriziano
Items : 3
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2.
2024
AO Ordine Mauriziano
AO Ordine Mauriziano
Colombo N; Biagioli E; Harano K; Galli F; Hudson E; Antill Y; Choi CH; Rabaglio M; Marmé F; Marth C; Parma G; Fariñas-Madrid L; Nishio S; Allan K; Lee YC; Piovano E; Pardo B; Nakagawa S; McQueen J; Zamagni C; Manso L; Takehara K; Tasca G; Ferrero A; Tognon G; Lissoni AA; Petrella M; Laudani ME; Rulli E; et alii...
Impact of different follow-up regimens on health-related quality of life and costs in endometrial cancer patients: Results from the TOTEM randomized trial. in Gynecologic oncology / Gynecol Oncol. 2024 May;184:150-159. doi: 10.1016/j.ygyno.2024.01.050. Epub 2024 Feb 3.
2024
ASL Città di Torino
AO Ordine Mauriziano
ASL Città di Torino
AO Ordine Mauriziano
Laudani ME; Pagano E; Piovano E; Fuso L; Evangelista A; Di Cuonzo D; Ciccone G; Mosconi P; Ferrero A; Rosato R; Pace L; Zola P;
Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study. in Anticancer research / Anticancer Res. 2022 Apr;42(4):2017-2022. doi: 10.21873/anticanres.15681.
2022
AO Ordine Mauriziano
AO Ordine Mauriziano
Gadducci A; Cosio S; Landoni F; Lissoni AA; Zola P; Laudani ME; Ardizzoia A; Gambino A; Sartori E;